Chang-Lin Mei a , Cheng Xue a , * , Sheng-Qiang Yu a , Bing Dai a , Jiang-Hua Chen b , Ying Li c , Li-Meng Chen d , Zhang-Suo Liu e , Yong-Gui Wu f , Zhao Hu g , Yan Zha h , Hong Liu i , Yong-Ze Zhuang j , Chun Zhang k , Xiang-Cheng Xiao l , Yue Wang m , Gui-Sen Li n , Yi-Yi Ma a , Lin Li a
19 March 2020
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, with a prevalence of 1/2,500–1/1,000, and it affects 1.25 million people in China. ADPKD is responsible for nearly 5% of end-stage renal disease cases, which leads to a major burden on public health. In 2016, the Chinese working group developed guidelines for the diagnosis and treatment of ADPKD, which promoted the clinical management of ADPKD in China. In the last 3 years, Chinese clinicians have deepened their understanding and standardized the management of ADPKD, and several basic and clinical studies on ADPKD have been conducted. In combination with international guidelines and research results, the working group updated the ADPKD guidelines in China. This guideline includes 5 chapters: introduction, diagnosis, kidney disease progression monitoring, treatment, and family planning. We highlight the main recommendations and suggestions of the ADPKD guidelines in this summary.